This study evaluated the long-term efficacy of globus pallidus internus (GPi) deep brain stimulation (DBS) in the treatment of craniofacial dystonia (Meige syndrome) and investigated the correlation between the volume of tissue activated (VTA) in the GPi and each subregion and movement score improvement. We retrospectively analyzed the clinical data of 13 patients with drug-refractory Meige syndrome who were treated with GPi DBS. The pre- and postoperative Burke–Fahn–Marsden Dystonia Rating Scale (BFMDRS) scores were compared. The relationships between the preoperative baseline variables and improvement in the BFMDRS-Movement (BFMDRS-M) score were analyzed. LEAD-DBS software was used for the three-dimensional reconstruction of the GPi and implanted electrodes. The correlations between the GPi-VTA and score improvement were analyzed. The average follow-up period was 36.6 ± 11.0 months (18–55 months). At 3 months after the stimulation and the final follow-up visit, the improvements in the BFMDRS-M score were 58.2 and 54.6%, and the improvements in the BFMDRS-Disability (BFMDRS-D) score were 53.6 and 51.7%, respectively. At the final follow-up visit, the improvements in the BFMDRS-M scores of the eye, mouth, and speech/swallowing were significant (P < 0.001). Age was an independent predictor of improvement in the BFMDRS-M score after DBS (P = 0.005). A decrease in the BFMDRS-M score was significantly positively correlated with the GPi-VTA (r = 0.757, P = 0.003). GPi DBS is an effective method for treating drug-refractory Meige syndrome. LEAD-DBS software can be used as an effective aid for visualization programming after DBS.

本研究评估了苍白球 (GPi) 脑深部刺激 (DBS) 治疗颅面肌张力障碍 (Meige 综合征) 的长期疗效，并研究了 GPi 中组织激活量 (VTA) 与各亚区的相关性和运动得分提高。我们回顾性分析了接受 GPi DBS 治疗的 13 例药物难治性梅格综合征患者的临床资料。比较了术前和术后 Burke-Fahn-Marsden 肌张力障碍评定量表 (BFMDRS) 的评分。分析了术前基线变量与 BFMDRS-Movement (BFMDRS-M) 评分改善之间的关系。LEAD-DBS 软件用于 GPi 和植入电极的三维重建。分析了GPi-VTA与分数提高之间的相关性。平均随访时间为 36.6 ± 11.0 个月（18-55 个月）。在刺激和最后一次随访后 3 个月，BFMDRS-M 评分的提高分别为 58.2% 和 54.6%，BFMDRS-Disability (BFMDRS-D) 评分的提高分别为 53.6% 和 51.7%。在最后一次随访中，眼睛、嘴巴和言语/吞咽的 BFMDRS-M 评分有显着改善（P  < 0.001)。年龄是 DBS 后 BFMDRS-M 评分改善的独立预测因素（P  = 0.005）。BFMDRS-M 评分的下降与 GPi-VTA 显着正相关（r  = 0.757，P  = 0.003）。GPi DBS是治疗药物难治性梅格综合征的有效方法。LEAD-DBS软件可以作为DBS之后可视化编程的有效辅助工具。